Top Markets
#1 Islamic Coin Islamic Coin +154.46%
#2 PulseChain PulseChain +48.38%
#3 Ergo Ergo +29.15%
#4 Not in Employment, Education, or Training Not in Employment, Education, or Training +16.40%
#5 RedStone RedStone +16.30%
#6 SkyAI SkyAI +10.37%
#7 Lighter Lighter +9.20%
#8 OPENLOOT OPENLOOT +8.93%
#9 Siren Siren +8.92%
#10 MarsCoin MarsCoin +8.84%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Biocartis Group N.V. Biocartis Group N.V.

Biocartis Group N.V.

BCART
Classement en actions #27526
Biocartis Group NV is a molecular diagnostics firm dedicated to improving... Biocartis Group NV is a molecular diagnostics firm dedicated to improving clinical care. Its innovative diagnostic solutions primarily serve the oncology sector, benefiting patients, medical professionals, insurers, and the broader healthcare ecosystem. The company's cornerstone is its exclusive Idylla molecular diagnostics platform, a sophisticated real-time polymerase chain reaction (PCR) system. This technology delivers crucial molecular data, aiding in the selection of appropriate treatments and the continuous monitoring of patient progress. Biocartis offers a range of diagnostic tests via the Idylla system, including mutation analysis for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Additionally, it provides Idylla panels for SARS-CoV-2/Flu/RSV, standalone SARS-CoV-2 tests, and the rapid host-response assessment, SeptiCyte RAPID. For research purposes, the company supplies various mutation assays, such as those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis has entered into strategic partnerships to broaden its impact. One such collaboration is with Amgen, focusing on evaluating Idylla RAS testing to enable swift, decentralized diagnostics and enhance the accessibility of RAS biomarker data through the Idylla platform and its associated RAS tests. Another key alliance is with Bristol-Myers Squibb Company, centered on the registration and application of the Idylla MSI test within the field of immuno-oncology treatments. Furthermore, a licensing, development, and commercialization agreement with GeneproDx is in place for the creation of the innovative ThyroidPrint genomic test, to be integrated onto the Idylla platform. Established in 2007, Biocartis maintains its corporate headquarters in Mechelen, Belgium.
Prix de l'action
$0.343985
Dernière synchronisation: 2024-07-23
Capitalisation boursière
$32.31M
Changement (1 jour)
11.88%
Changement (1 an)
0.00%
Pays
BE
Échange Biocartis Group N.V. (BCART)

Catégorie

Healthcare
Le prix BCART avec la capitalisation boursière de B
Biocartis Group N.V. Biocartis Group N.V.
BCART
$0.343985
Capitalisation boursière de Biocartis Group N.V.(BCART)
Capitalisation boursière: $32.31M
En August 2026, Biocartis Group N.V. a une capitalisation boursière de $32.31M. Cela fait de Biocartis Group N.V. la 27526th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Biocartis Group N.V. du 2015 au 2026
BCART par rapport au top 5 des plus populaires stocks
Prix pour BCART L’actif B La capitalisation boursière de B Résultats
Biocartis Group N.V. Biocartis Group N.V.
$56,439.04 $32.31M
NVIDIA Corporation NVIDIA Corporation
NVDA
$5.301T +16,407,312.61%
Biocartis Group N.V. Biocartis Group N.V.
$49,337.40 $32.31M
Apple Inc. Apple Inc.
AAPL
$4.634T +14,342,793.63%
Biocartis Group N.V. Biocartis Group N.V.
$44,110.86 $32.31M
Alphabet Inc. Alphabet Inc.
GOOG
$4.143T +12,823,383.89%
Biocartis Group N.V. Biocartis Group N.V.
$38,216.52 $32.31M
Microsoft Corporation Microsoft Corporation
MSFT
$3.589T +11,109,838.98%
Biocartis Group N.V. Biocartis Group N.V.
$30,418.31 $32.31M
Amazon.com, Inc. Amazon.com, Inc.
AMZN
$2.857T +8,842,816.89%